|
US3906092A
(en)
|
1971-11-26 |
1975-09-16 |
Merck & Co Inc |
Stimulation of antibody response
|
|
CA1335429C
(en)
|
1986-03-07 |
1995-05-02 |
Geoffrey L. Smith |
Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
|
|
US6162620A
(en)
|
1986-03-07 |
2000-12-19 |
Cogent Limited |
Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
|
|
US6207161B1
(en)
|
1986-07-16 |
2001-03-27 |
City Of Hope |
Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
|
|
DK0737750T3
(da)
|
1989-03-21 |
2003-09-01 |
Vical Inc |
Ekspression af exogene polynucleotidsekvenser i vertebrater
|
|
WO1993014778A1
(en)
|
1992-01-23 |
1993-08-05 |
Vical, Inc. |
Ex vivo gene transfer
|
|
IL112820A0
(en)
|
1994-03-07 |
1995-05-26 |
Merck & Co Inc |
Coordinate in vivo gene expression
|
|
WO1995026204A1
(en)
|
1994-03-25 |
1995-10-05 |
Isis Pharmaceuticals, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
EP0802980A1
(en)
|
1994-06-02 |
1997-10-29 |
Chiron Corporation |
Nucleic acid immunization using a virus-based infection/transfection system
|
|
AU2809897A
(en)
|
1996-04-23 |
1997-11-12 |
Wistar Institute Of Anatomy And Biology, The |
Novel human cytomegalovirus dna constructs and uses therefor
|
|
US6074645A
(en)
|
1996-11-12 |
2000-06-13 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
|
US6562345B1
(en)
|
1996-11-12 |
2003-05-13 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
|
US6183752B1
(en)
*
|
1997-02-05 |
2001-02-06 |
Pasteur Merieux Serums Et Vaccins |
Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
|
|
EP1021548A1
(en)
|
1997-10-07 |
2000-07-26 |
University Of Maryland Biotechnology Institute |
Method for introducing and expressing rna in animal cells
|
|
WO1999033982A2
(en)
|
1997-12-23 |
1999-07-08 |
Chiron Corporation |
Human genes and gene expression products i
|
|
DE19910044A1
(de)
|
1999-03-08 |
2000-09-14 |
Bodo Plachter |
Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
|
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
|
ATE289630T1
(de)
|
1999-09-09 |
2005-03-15 |
Curevac Gmbh |
Transfer von mrnas unter verwendung von polykationischen verbindungen
|
|
AU7725500A
(en)
|
1999-09-30 |
2001-04-30 |
National Jewish Medical And Research Center |
Method for inhibition of pathogenic microorganisms
|
|
US7060291B1
(en)
|
1999-11-24 |
2006-06-13 |
Transave, Inc. |
Modular targeted liposomal delivery system
|
|
US6835383B2
(en)
|
2000-03-23 |
2004-12-28 |
City Of Hope |
Protein kinase deficient, immunologically active CMVpp65 mutants
|
|
AU2001275423B2
(en)
|
2000-06-09 |
2007-01-11 |
Regulon, Inc. |
Encapsulation of polynucleotides and drugs into targeted liposomes
|
|
US7204990B1
(en)
|
2000-11-28 |
2007-04-17 |
Medimmune Vaccines, Inc. |
Attenuation of cytomegalovirus virulence
|
|
EP2305699B1
(de)
|
2001-06-05 |
2014-08-13 |
CureVac GmbH |
Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
AU2003235707A1
(en)
*
|
2002-01-18 |
2003-07-30 |
Curevac Gmbh |
Immunogenic preparations and vaccines on the basis of mrna
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
ATE471335T1
(de)
*
|
2002-12-23 |
2010-07-15 |
Vical Inc |
Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
|
|
WO2004076645A2
(en)
|
2003-02-27 |
2004-09-10 |
University Of Massachusetts |
Compositions and methods for cytomegalovirus treatment
|
|
WO2005009346A2
(en)
|
2003-06-24 |
2005-02-03 |
Mirus Corporation |
Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
|
|
ATE432285T1
(de)
*
|
2003-07-11 |
2009-06-15 |
Alphavax Inc |
Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
|
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
|
AU2004280143A1
(en)
|
2003-10-11 |
2005-04-21 |
Tekmira Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
|
EP1691780A2
(en)
|
2003-11-21 |
2006-08-23 |
Alza Corporation |
Gene delivery mediated by liposome-dna complex with cleavable peg surface modification
|
|
JP4764426B2
(ja)
|
2004-06-07 |
2011-09-07 |
プロチバ バイオセラピューティクス インコーポレイティッド |
カチオン性脂質および使用方法
|
|
DE102004035227A1
(de)
|
2004-07-21 |
2006-02-16 |
Curevac Gmbh |
mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
|
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
|
US7976845B2
(en)
|
2004-11-29 |
2011-07-12 |
The Council Of The Queensland Institute Of Medical Research |
Human cytomegalovirus immunotherapy
|
|
US9068969B2
(en)
|
2004-12-28 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Cell based methods and systems for the identification of RNA regulatory sequences and compounds that modulate their functions
|
|
EP2287608B1
(en)
|
2005-03-11 |
2014-01-08 |
Firalis SAS |
Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
CA2628300C
(en)
|
2005-11-02 |
2018-04-17 |
Protiva Biotherapeutics, Inc. |
Modified sirna molecules and uses thereof
|
|
US9149543B2
(en)
|
2005-12-15 |
2015-10-06 |
The Trustees Of The University Of Pennsylvania |
Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
|
|
DE102006007433A1
(de)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
|
|
JP5822433B2
(ja)
|
2006-06-07 |
2015-11-24 |
ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ |
ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
|
|
AU2007280690C1
(en)
|
2006-07-31 |
2012-08-23 |
Curevac Gmbh |
Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
|
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
|
US9226959B2
(en)
|
2008-01-31 |
2016-01-05 |
Curevac Ag |
Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvant
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
EP3156069B8
(en)
*
|
2008-06-20 |
2020-10-21 |
Duke University |
Compositions, methods, and kits for eliciting an immune response
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
AU2015210364B2
(en)
|
2008-10-09 |
2017-03-09 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
JP5777519B2
(ja)
|
2008-10-09 |
2015-09-09 |
テクミラ ファーマシューティカルズ コーポレイション |
改良されたアミノ脂質および核酸の送達方法
|
|
US20100112042A1
(en)
|
2008-10-16 |
2010-05-06 |
Mdrna, Inc. |
Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
|
|
CA3006395C
(en)
|
2008-11-07 |
2022-05-31 |
Massachusetts Institute Of Technology |
Aminoalcohol lipidoids and uses thereof
|
|
PL2355851T3
(pl)
|
2008-11-10 |
2018-08-31 |
Arbutus Biopharma Corporation |
Nowe lipidy i kompozycje do dostarczania środków terapeutycznych
|
|
WO2010057203A2
(en)
|
2008-11-17 |
2010-05-20 |
The Board Of Regents Of The University Of Texas System |
Hdl particles for delivery of nucleic acids
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
|
US9732337B2
(en)
|
2009-06-16 |
2017-08-15 |
The United Stated of America, as represented by the Secretary, Department of Health & Human Services |
RNA nanoparticles and nanotubes
|
|
EP2451475A2
(en)
|
2009-07-06 |
2012-05-16 |
Novartis AG |
Self replicating rna molecules and uses thereof
|
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
|
US20110244026A1
(en)
|
2009-12-01 |
2011-10-06 |
Braydon Charles Guild |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
|
SG10201502271RA
(en)
|
2010-04-06 |
2015-05-28 |
Vakzine Projekt Man Gmbh |
Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof
|
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
SI2590676T1
(sl)
|
2010-07-06 |
2016-11-30 |
Glaxosmithkline Biologicals, S.A. |
Virionu podobni delci za dajanje za samorepliciranje RNA molekul
|
|
CN107648604A
(zh)
|
2010-07-30 |
2018-02-02 |
库瑞瓦格股份公司 |
聚合物载体运载物复合物及聚合物载体的用途
|
|
EP2600901B1
(en)
|
2010-08-06 |
2019-03-27 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
WO2012030901A1
(en)
|
2010-08-31 |
2012-03-08 |
Novartis Ag |
Small liposomes for delivery of immunogen-encoding rna
|
|
SI3970742T1
(sl)
|
2010-08-31 |
2022-08-31 |
Glaxosmithkline Biologicals S.A. |
Pegilirani liposomi za dostavo RNA, ki kodira imunogen
|
|
EP2614072A4
(en)
|
2010-09-09 |
2014-03-19 |
Univ Virginia Commonwealth |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
MX2013003681A
(es)
|
2010-10-01 |
2013-11-20 |
Moderna Therapeutics Inc |
Ácidos nucleicos manipulados y métodos de uso de los mismos.
|
|
BR112013008700B8
(pt)
*
|
2010-10-11 |
2022-10-04 |
Novartis Ag |
Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
|
|
MX352974B
(es)
|
2011-01-31 |
2017-12-15 |
Univ Pennsylvania |
Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
WO2012135805A2
(en)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Delivery and formulation of engineered nucleic acids
|
|
EP2710136A4
(en)
|
2011-05-17 |
2015-01-21 |
Moderna Therapeutics Inc |
MANIPULATED NUCLEIC ACIDS AND USE METHOD FOR NON-HUMAN SPINE
|
|
LT2717893T
(lt)
|
2011-06-08 |
2019-08-12 |
Translate Bio, Inc. |
Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai
|
|
US8916696B2
(en)
|
2011-06-12 |
2014-12-23 |
City Of Hope |
Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
|
|
US11058762B2
(en)
|
2011-07-06 |
2021-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
US11896636B2
(en)
|
2011-07-06 |
2024-02-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic combination compositions and uses thereof
|
|
TWI570240B
(zh)
|
2011-09-09 |
2017-02-11 |
默沙東公司 |
作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
|
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
BR112014008694A2
(pt)
*
|
2011-10-11 |
2017-06-20 |
Novartis Ag |
moléculas de ácido nucleico policistrônico recombinante
|
|
US20140348863A1
(en)
|
2011-10-12 |
2014-11-27 |
Alessia Bianchi |
Cmv antigens and uses thereof
|
|
EP4074694A1
(en)
|
2011-10-27 |
2022-10-19 |
Massachusetts Institute Of Technology |
Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof
|
|
CN107875382B
(zh)
|
2011-11-11 |
2024-03-08 |
变异生物技术公司 |
用于治疗巨细胞病毒的组合物和方法
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
US20140378538A1
(en)
|
2011-12-14 |
2014-12-25 |
Moderma Therapeutics, Inc. |
Methods of responding to a biothreat
|
|
WO2013090186A1
(en)
|
2011-12-14 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleic acids, and acute care uses thereof
|
|
SMT202200355T1
(it)
|
2011-12-16 |
2022-11-18 |
Modernatx Inc |
Composizioni di mrna modificato
|
|
CA2859691A1
(en)
|
2011-12-21 |
2013-06-27 |
Moderna Therapeutics, Inc. |
Methods of increasing the viability or longevity of an organ or organ explant
|
|
US20130195851A1
(en)
|
2011-12-23 |
2013-08-01 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
|
PL3144389T3
(pl)
|
2011-12-30 |
2018-10-31 |
Cellscript, Llc |
WYTWARZANIE I STOSOWANIE ZSYNTETYZOWANEGO IN VITRO ssRNA DO WPROWADZANIA DO SSACZYCH KOMÓREK W CELU INDUKCJI EFEKTU BIOLOGICZNEGO LUB BIOCHEMICZNEGO
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
US10322089B2
(en)
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
EP2834260A4
(en)
|
2012-04-02 |
2016-08-10 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US10245229B2
(en)
|
2012-06-08 |
2019-04-02 |
Translate Bio, Inc. |
Pulmonary delivery of mRNA to non-lung target cells
|
|
GB2513768B
(en)
|
2012-07-06 |
2015-04-15 |
Novartis Ag |
Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins
|
|
CN104838000B
(zh)
*
|
2012-07-27 |
2022-12-20 |
希望之城 |
一种递送ul128复合体和预防cmv感染的mva疫苗
|
|
EP2885419A4
(en)
|
2012-08-14 |
2016-05-25 |
Moderna Therapeutics Inc |
ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
|
|
SG11201501623PA
(en)
|
2012-10-30 |
2015-05-28 |
Redvax Gmbh |
Recombinant particle based vaccines against human cytomegalovirus infection
|
|
EP2922554B1
(en)
|
2012-11-26 |
2022-02-23 |
ModernaTX, Inc. |
Terminally modified rna
|
|
JP2016501023A
(ja)
|
2012-12-04 |
2016-01-18 |
メルク・シャープ・アンド・ドーム・コーポレーションＭ |
条件付き複製ウイルスベクター
|
|
WO2014089486A1
(en)
|
2012-12-07 |
2014-06-12 |
Shire Human Genetic Therapies, Inc. |
Lipidic nanoparticles for mrna delivering
|
|
WO2014089239A1
(en)
|
2012-12-07 |
2014-06-12 |
Alnylam Pharmaceuticals, Inc. |
Improved nucleic acid lipid particle formulations
|
|
WO2014093574A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
|
EP2931319B1
(en)
|
2012-12-13 |
2019-08-21 |
ModernaTX, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
PL2970456T3
(pl)
|
2013-03-14 |
2022-01-31 |
Translate Bio, Inc. |
Sposoby i kompozycje do dostarczania przeciwciał kodowanych mrna
|
|
EP3431592A1
(en)
|
2013-03-14 |
2019-01-23 |
Translate Bio, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US10342760B2
(en)
|
2013-03-15 |
2019-07-09 |
The University Of British Columbia |
Lipid nanoparticles for transfection and related methods
|
|
EP4279610A3
(en)
|
2013-03-15 |
2024-01-03 |
ModernaTX, Inc. |
Ribonucleic acid purification
|
|
US10590161B2
(en)
|
2013-03-15 |
2020-03-17 |
Modernatx, Inc. |
Ion exchange purification of mRNA
|
|
US10138507B2
(en)
|
2013-03-15 |
2018-11-27 |
Modernatx, Inc. |
Manufacturing methods for production of RNA transcripts
|
|
WO2014144039A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
EP2994167B1
(en)
|
2013-05-06 |
2020-05-06 |
Alnylam Pharmaceuticals, Inc. |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
CN105555757A
(zh)
|
2013-07-23 |
2016-05-04 |
普洛体维生物治疗公司 |
用于递送信使rna的组合物和方法
|
|
ES2747762T3
(es)
|
2013-08-21 |
2020-03-11 |
Curevac Ag |
Vacuna contra el virus respiratorio sincitial (RSV)
|
|
US9950056B2
(en)
|
2013-09-24 |
2018-04-24 |
Duke University |
Compositions, methods and kits for eliciting an immune response
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
WO2015052570A1
(en)
*
|
2013-10-07 |
2015-04-16 |
Medizinische Universität Wien |
Implant and method for improving coaptation of an atrioventricular valve
|
|
AU2014337156A1
(en)
|
2013-10-18 |
2016-05-12 |
Modernatx, Inc. |
Compositions and methods for tolerizing cellular systems
|
|
EP3871696B1
(en)
|
2013-10-22 |
2025-03-19 |
Translate Bio, Inc. |
Lipid formulations for delivery of messenger rna
|
|
ES2868427T3
(es)
*
|
2013-12-03 |
2021-10-21 |
Hookipa Biotech Ag |
Vacunas contra el CMV
|
|
CA2931853C
(en)
|
2013-12-11 |
2023-10-03 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines
|
|
US10059655B2
(en)
|
2013-12-19 |
2018-08-28 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
WO2015110659A1
(en)
|
2014-01-27 |
2015-07-30 |
Bionor Immuno As |
Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
|
|
WO2015148247A1
(en)
|
2014-03-24 |
2015-10-01 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for the treatment of ocular diseases
|
|
AU2015251221A1
(en)
|
2014-04-23 |
2016-10-27 |
CARIPLO, Fondazione |
Human cytomegalovirus vaccine compositions and method of producing the same
|
|
WO2015165480A1
(en)
|
2014-04-30 |
2015-11-05 |
Institute For Research In Biomedicine |
Human cytomegalovirus vaccine compositions and method of producing the same
|
|
RS66380B1
(sr)
|
2014-04-23 |
2025-02-28 |
Modernatx Inc |
Vakcine nukleinske kiseline
|
|
PE20170301A1
(es)
|
2014-05-08 |
2017-03-30 |
Pfizer |
Medios y metodos para el tratamiento cmv
|
|
AR100608A1
(es)
|
2014-05-27 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Complejos de citomegalovirus y usos de los mismos
|
|
US10286086B2
(en)
|
2014-06-19 |
2019-05-14 |
Modernatx, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
IL298516B2
(en)
|
2014-06-25 |
2025-03-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
|
|
CN114344275A
(zh)
|
2014-07-02 |
2022-04-15 |
川斯勒佰尔公司 |
信使rna的包封
|
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3169783A4
(en)
|
2014-07-17 |
2018-10-03 |
Modernatx, Inc. |
Terminal modifications of polynucleotides
|
|
ES2969956T3
(es)
|
2014-09-05 |
2024-05-23 |
Novartis Ag |
Lípidos y composiciones lipídicas para el suministro de agentes activos
|
|
EP3015475A1
(en)
|
2014-10-31 |
2016-05-04 |
Novartis AG |
Mammalian cells expressing cytomegalovirus antigens
|
|
EP3031822A1
(en)
|
2014-12-08 |
2016-06-15 |
Novartis AG |
Cytomegalovirus antigens
|
|
EP3247363A4
(en)
|
2015-01-21 |
2018-10-03 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
EP3048114A1
(en)
|
2015-01-22 |
2016-07-27 |
Novartis AG |
Cytomegalovirus antigens and uses thereof
|
|
EP3047856A1
(en)
|
2015-01-23 |
2016-07-27 |
Novartis AG |
Cmv antigens and uses thereof
|
|
US20180298404A1
(en)
|
2015-02-10 |
2018-10-18 |
Oregon Health & Science University |
Methods and compositions useful in generating non canonical cd8+ t cell responses
|
|
WO2016133881A1
(en)
|
2015-02-16 |
2016-08-25 |
Kamil Jeremy P |
Method of altering expression of alternative viral glycoprotein complexes
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
US11559570B2
(en)
|
2015-05-15 |
2023-01-24 |
CureVac SE |
Prime-boost regimens involving administration of at least one mRNA construct
|
|
WO2016201377A1
(en)
|
2015-06-10 |
2016-12-15 |
Moderna Therapeutics, Inc. |
Targeted adaptive vaccines
|
|
WO2016203025A1
(en)
|
2015-06-17 |
2016-12-22 |
Curevac Ag |
Vaccine composition
|
|
CA2990202A1
(en)
|
2015-06-29 |
2017-01-05 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
EP4218805A1
(en)
|
2015-07-21 |
2023-08-02 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
WO2017020026A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
WO2017019935A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Multimeric mrna
|
|
US20180237849A1
(en)
|
2015-08-17 |
2018-08-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
ES2910425T3
(es)
|
2015-09-17 |
2022-05-12 |
Modernatx Inc |
Compuestos y composiciones para la administración intracelular de agentes terapéuticos
|
|
ES2810701T5
(es)
|
2015-10-05 |
2024-07-11 |
Modernatx Inc |
Procedimientos para la administración terapéutica de medicamentos de ácido ribonucleico mensajero
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
TN2018000152A1
(en)
|
2015-10-22 |
2019-10-04 |
Modernatx Inc |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
EP3364982A4
(en)
|
2015-10-22 |
2019-04-17 |
ModernaTX, Inc. |
VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
|
|
US20180318409A1
(en)
|
2015-10-22 |
2018-11-08 |
Modernatx, Inc. |
Cancer vaccines
|
|
AU2016342049B2
(en)
|
2015-10-22 |
2023-05-18 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
EP4349405A3
(en)
|
2015-10-22 |
2024-06-19 |
ModernaTX, Inc. |
Respiratory virus vaccines
|
|
JP7687767B2
(ja)
|
2015-10-22 |
2025-06-03 |
モデルナティエックス インコーポレイテッド |
呼吸器合胞体ウイルスワクチン
|
|
CN118846026A
(zh)
|
2015-10-22 |
2024-10-29 |
摩登纳特斯有限公司 |
广谱流感病毒疫苗
|
|
JP6921833B2
(ja)
*
|
2015-10-22 |
2021-08-18 |
モデルナティーエックス， インコーポレイテッド |
ヒトサイトメガロウイルスワクチン
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
SMT202300052T1
(it)
|
2015-10-28 |
2023-05-12 |
Acuitas Therapeutics Inc |
Nuovi lipidi e formulazioni di nanoparticelle lipidiche per il rilascio di acidi nucleici
|
|
WO2017099823A1
(en)
|
2015-12-10 |
2017-06-15 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
|
CA3007108A1
(en)
|
2015-12-17 |
2017-06-22 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
|
US20210206818A1
(en)
|
2016-01-22 |
2021-07-08 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
WO2017153936A1
(en)
|
2016-03-10 |
2017-09-14 |
Novartis Ag |
Chemically modified messenger rna's
|
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
|
US20190382774A1
(en)
|
2016-05-18 |
2019-12-19 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
US11801227B2
(en)
|
2016-05-18 |
2023-10-31 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
SG11201810162PA
(en)
|
2016-05-18 |
2018-12-28 |
Modernatx Inc |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
|
JP2019519601A
(ja)
|
2016-05-18 |
2019-07-11 |
モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． |
急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド
|
|
MA45041A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1
|
|
WO2017201332A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
|
AU2017268394A1
(en)
|
2016-05-18 |
2019-01-03 |
Modernatx, Inc. |
Polynucleotides encoding relaxin
|
|
CA3024507A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
|
|
WO2017201342A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
WO2017201333A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
|
|
JP2019519516A
(ja)
|
2016-05-18 |
2019-07-11 |
モデルナティーエックス， インコーポレイテッド |
がんの治療のためのｍＲＮＡ併用療法
|
|
US10967057B2
(en)
|
2016-06-02 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Zika viral antigen constructs
|
|
EP3468537A1
(en)
|
2016-06-14 |
2019-04-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CA3036831A1
(en)
|
2016-09-14 |
2018-03-22 |
Modernatx, Inc. |
High purity rna compositions and methods for preparation thereof
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
EP3532613A4
(en)
|
2016-10-26 |
2020-05-06 |
ModernaTX, Inc. |
METHOD AND COMPOSITIONS FOR RNA MAPPING
|
|
AU2017347837A1
(en)
|
2016-10-26 |
2019-06-06 |
Modernatx, Inc. |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
US20200163878A1
(en)
|
2016-10-26 |
2020-05-28 |
Curevac Ag |
Lipid nanoparticle mrna vaccines
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP3538146A4
(en)
|
2016-11-11 |
2020-07-15 |
ModernaTX, Inc. |
INFLUENZA VACCINE
|
|
US11103578B2
(en)
|
2016-12-08 |
2021-08-31 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
US11384352B2
(en)
|
2016-12-13 |
2022-07-12 |
Modernatx, Inc. |
RNA affinity purification
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
JP2020515522A
(ja)
|
2017-01-27 |
2020-05-28 |
ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド |
免疫応答を誘導するヘルペスウイルスエンベロープタンパク質の組み合わせのワクチン組成物
|
|
SG11201906895WA
(en)
|
2017-02-01 |
2019-08-27 |
Modernatx Inc |
Rna cancer vaccines
|
|
AU2018214556A1
(en)
|
2017-02-01 |
2019-08-15 |
Modernatx, Inc. |
Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
|
|
WO2018144778A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Polynucleotide secondary structure
|
|
EP3582790A4
(en)
|
2017-02-16 |
2020-11-25 |
ModernaTX, Inc. |
VERY POWERFUL IMMUNOGENIC COMPOSITIONS
|
|
WO2018157009A1
(en)
|
2017-02-24 |
2018-08-30 |
Modernatx, Inc. |
Nucleic acid-based therapy of muscular dystrophies
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
US11464848B2
(en)
|
2017-03-15 |
2022-10-11 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
|
US20200038499A1
(en)
|
2017-03-22 |
2020-02-06 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
EP3607074A4
(en)
|
2017-04-05 |
2021-07-07 |
Modernatx, Inc. |
REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
|
|
MA49463A
(fr)
|
2017-04-26 |
2021-05-05 |
Modernatx Inc |
Vaccin contre le virus de l'herpès simplex
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
|
EP3668979A4
(en)
|
2017-08-18 |
2021-06-02 |
Modernatx, Inc. |
METHOD OF HPLC ANALYSIS
|
|
US20200254086A1
(en)
|
2017-08-18 |
2020-08-13 |
Moderna TX, Inc. |
Efficacious mrna vaccines
|
|
EP3668971B8
(en)
|
2017-08-18 |
2024-05-29 |
ModernaTX, Inc. |
Rna polymerase variants
|
|
EP3668977A4
(en)
|
2017-08-18 |
2021-04-21 |
Modernatx, Inc. |
HPLC ANALYTICAL PROCESSES
|
|
WO2019055807A1
(en)
|
2017-09-14 |
2019-03-21 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZIKA VIRUS
|
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
|
CA3083102A1
(en)
|
2017-11-21 |
2019-05-31 |
Modernatx, Inc. |
Epstein-barr virus vaccines
|
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
|
SG11202012770RA
(en)
|
2018-06-27 |
2021-01-28 |
Modernatx Inc |
Personalized cancer vaccine epitope selection
|
|
CA3111836A1
(en)
|
2018-09-13 |
2020-03-19 |
Modernatx, Inc. |
Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
|
|
EP3852732A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Peg lipids and uses thereof
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CN112996854B
(zh)
|
2018-09-19 |
2024-08-30 |
摩登纳特斯有限公司 |
高纯度peg脂质和其用途
|
|
JP2022506839A
(ja)
|
2018-11-07 |
2022-01-17 |
モデルナティエックス インコーポレイテッド |
Ｒｎａがんワクチン
|
|
MA55037A
(fr)
|
2019-02-20 |
2021-12-29 |
Modernatx Inc |
Variants d'arn polymérase pour le coiffage co-transcriptionnel
|
|
KR20210149727A
(ko)
|
2019-03-11 |
2021-12-09 |
모더나티엑스, 인크. |
유가식(fed-batch) 시험관내 전사 공정
|
|
WO2020190750A1
(en)
|
2019-03-15 |
2020-09-24 |
Modernatx, Inc. |
Hiv rna vaccines
|
|
WO2020243561A1
(en)
|
2019-05-31 |
2020-12-03 |
Modernatx, Inc. |
Expanded t cell assay
|
|
BR112022002548A2
(pt)
|
2019-08-14 |
2022-06-14 |
Modernatx Inc |
Processos para purificar produtos a jusante de transcrição in vitro
|
|
EP4028030A4
(en)
|
2019-09-11 |
2023-09-27 |
ModernaTX, Inc. |
VACCINE AGAINST HUMAN CYTOMEGALOVIRUS
|
|
US20220349006A1
(en)
|
2019-09-19 |
2022-11-03 |
Moderna TX, Inc. |
Cap guides and methods of use thereof for rna mapping
|
|
US20210217484A1
(en)
|
2020-01-10 |
2021-07-15 |
Modernatx, Inc. |
Variational autoencoder for biological sequence generation
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
CN115103682A
(zh)
|
2020-01-30 |
2022-09-23 |
摩登纳特斯有限公司 |
呼吸道病毒免疫组合物
|
|
EP4100052A2
(en)
|
2020-02-07 |
2022-12-14 |
ModernaTX, Inc. |
Sars-cov-2 mrna domain vaccines
|
|
WO2021211343A1
(en)
|
2020-04-13 |
2021-10-21 |
Modernatx, Inc. |
Zika virus mrna vaccines
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
EP4149484A4
(en)
|
2020-05-15 |
2024-10-02 |
ModernaTX, Inc. |
RNA FORMULATIONS FOR HIGH VOLUME DELIVERY
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
US20230190761A1
(en)
|
2020-05-21 |
2023-06-22 |
Modernatx, Inc. |
Methylene blue stabilized mrna compositions
|
|
US20230287437A1
(en)
|
2020-06-05 |
2023-09-14 |
Modernatx, Inc. |
Bacterial strains for dna production
|